CD8A and neoplasm: Arguing that poor tumor immunogenicity and defective DC maturation result in an impaired priming of cytotoxic CD8+ T cells, the ex vivo exposure of DCs to tumor antigens with concomitant stimulatory signals has been proposed to trigger an antitumor response.